BIO.B Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bio-Rad Laboratories Inc (BIO.B) is not a strong buy for a beginner, long-term investor at this time. The lack of positive momentum in technical indicators, weak financial performance in the latest quarter, and mixed analyst ratings suggest waiting for clearer signs of growth or stability before investing.
The MACD is positive and expanding, suggesting some bullish momentum. However, the RSI is neutral at 70.584, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 268.198, with resistance at 275.407 and support at 260.99. Overall, the technical indicators do not strongly support a buy decision.
Hedge funds are significantly increasing their positions in the stock, with a 333305.80% increase in buying activity over the last quarter. This indicates institutional confidence in the company.
The company's Q4 financials show a significant decline in net income (-200.59% YoY), EPS (-204.22% YoY), and gross margin (-2.89% YoY). Analysts have lowered price targets due to weak guidance and messy margins. Additionally, there is no recent news or event-driven catalysts to drive the stock upward.
In Q4 2025, revenue increased by 3.85% YoY to $693.2 million. However, net income dropped drastically by -200.59% YoY to $720 million, and EPS fell by -204.22% YoY to 26.65. Gross margin also declined to 49.74%, down -2.89% YoY, indicating deteriorating profitability.
Analysts have mixed views. Wells Fargo lowered the price target to $320 from $340 and maintained an Equal Weight rating, citing weak guidance and a Q4 miss. UBS lowered the price target to $335 from $350 but maintained a Buy rating, noting some bright spots despite messy margins and headwinds. Overall, analysts are cautious about the stock's near-term prospects.
